The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial
Jeffrey How(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(Sarah Cannon), Abdulrahman Abonofal(The University of Texas MD Anderson Cancer Center), Lois M. Ramondetta(The University of Texas MD Anderson Cancer Center), Bettzy Stephen(The University of Texas MD Anderson Cancer Center), Fei Yang(Roche (Switzerland)), Mingxuan Xu(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Daniel D. Karp(The University of Texas MD Anderson Cancer Center)
Cited by 25
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Monitoring dopants by Raman scattering in an electrochemically top-gated graphene transistor
|Nature Nanotechnology|2008|3.6k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k